We maintain a BUY rating but lower our target price by 16.9% due to a higher market risk premium as well as a lower forecast for 2018 earnings. H1 2018 recurring NPAT was weak (-20.7% YoY) due to (1) a low sales volume recovery of 17.2% YoY because of a g